Connor, Clark & Lunn Investment Management (CC&L)’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.2M | Sell |
1,019,951
-62,811
| -6% | -$1.22M | 0.05% | 303 |
|
|
2025
Q4 | $23.3M | Sell |
1,082,762
-662,289
| -38% | -$14M | 0.06% | 260 |
|
|
2025
Q3 | $33.6M | Buy |
1,745,051
+1,129,610
| +184% | +$20.1M | 0.11% | 182 |
|
|
2025
Q2 | $10.5M | Buy |
615,441
+370,672
| +151% | +$15.8M | 0.04% | 388 |
|
|
2025
Q1 | $15.6M | Buy |
244,769
+97,533
| +66% | +$10.3M | 0.07% | 236 |
|
|
2024
Q4 | $17.9M | Buy |
147,236
+68,992
| +88% | +$8.46M | 0.08% | 192 |
|
|
2024
Q3 | $9.77M | Buy |
78,244
+18,095
| +30% | +$2.5M | 0.05% | 283 |
|
|
2024
Q2 | $9.5M | Buy |
60,149
+58,096
| +2,830% | +$7.46M | 0.04% | 285 |
|
|
2024
Q1 | $266K | Buy |
+2,053
| New | +$251K | ﹤0.01% | 1312 |
|
|
2023
Q4 | – | Sell |
-78,566
| Closed | -$9.52M | – | 1549 |
|
|
2023
Q3 | $9.52M | Sell |
78,566
-19,577
| -20% | -$2.21M | 0.05% | 253 |
|
|
2023
Q2 | $11.2M | Sell |
98,143
-21,523
| -18% | -$2.78M | 0.06% | 238 |
|
|
2023
Q1 | $16.5M | Buy |
119,666
+3,370
| +3% | +$437K | 0.09% | 179 |
|
|
2022
Q4 | $15.1M | Sell |
116,296
-41,435
| -26% | -$4.8M | 0.09% | 176 |
|
|
2022
Q3 | $17.4M | Buy |
157,731
+139,890
| +784% | +$14.1M | 0.11% | 138 |
|
|
2022
Q2 | $1.34M | Buy |
+17,841
| New | +$1.31M | 0.01% | 558 |
|
|
2021
Q2 | – | Sell |
-5,184
| Closed | -$386K | – | 1096 |
|
|
2021
Q1 | $386K | Sell |
5,184
-2,272
| -30% | -$210K | ﹤0.01% | 824 |
|
|
2020
Q4 | $1.27M | Sell |
7,456
-1,041
| -12% | -$154K | 0.01% | 593 |
|
|
2020
Q3 | $1.19M | Buy |
+8,497
| New | +$1.29M | 0.01% | 586 |
|
|
2018
Q4 | – | Sell |
-1,550
| Closed | -$250K | – | 1046 |
|
|
2018
Q3 | $250K | Buy |
+1,550
| New | +$212K | ﹤0.01% | 814 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
